Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study

<h2>ABSTRACT</h2><h3>Objective</h3> To investigate possible variations in treatment response to secukinumab at distinct anatomic joint locations in patients with psoriatic arthritis (PsA) in routine clinical care. <h3>Methods</h3> Patients with PsA monitored in 9 registries contributing to the European Spondyloarthritis Research Collaboration Network were included in this study if at least 1 joint from the 28-joint count was clinically swollen at the start of treatment with secukinumab. The primary outcome was time to first resolution of clinical joint swelling at each joint location, excluding the shoulder, during a follow-up of 2 years. Estimated hazard ratios (HRs) for resolution between different joint locations were compared with interval-censored mixed-effects transformation models adjusted for age, sex, and previous biologic/targeted synthetic disease-modifying antirheumatic drug (DMARD). <h3>Results</h3> A total of 590 patients with 2794 swollen joints at the initiation of secukinumab were included (mean [SD] age 51.7 [12.3] years, 54% female patients, 77% co-treatment with conventional synthetic DMARDs). Compared with the wrist, the elbow had a higher rate of resolution of joint swelling (HR = 1.75, 95% CI=1.10-2.79). The metacarpophalangeal joints (MCP) 4 and 5 (HR = 2.01, 95% CI=1.40-2.88 and HR=1.98, 95% CI=1.28-3.06, respectively), as well as most proximal interphalangeal joints (PIP), except PIP3, had a higher rate of resolution compared with the wrist. No significant difference in the resolution of joint swelling was found for the wrist compared with MCP2, MCP3, PIP3, and the knee. <h3>Conclusions</h3> In PsA, the time to resolution of joint swelling after initiation of secukinumab differs between distinct joint locations.

Authors

Institutions

Publication Details

Journal
EULAR Rheumatology Open
Published
2025-10-01
DOI
https://doi.org/10.1016/j.ero.2025.09.009
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study

Ediz Dalkılıç, Stefano Gentileschi, Vappu Rantalaiho, Johan K. Wallman et al.
EULAR Rheumatology Open
Spondyloarthritis Studies and Treatments
article

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study

Ediz Dalkılıç, Stefano Gentileschi, Vappu Rantalaiho, Johan K. Wallman, Rosemary Hollick, Gerður Gröndal, Florenzo Iannone, Adrian Ciurea, Brigitte Michelsen, Patrícia Nero, Raphael Micheroli, Belkıs Nihan Coşkun, Karin Laas, Anne Gitte Loft, Michael John Nissen, Ritva Peltomaa, Lykke Midtbøll Ørnbjerg, Burkhard Möller, Björn Guðbjörnsson, Isabel Castrejón, Merete Lund Hetland, H. Mann, Anne C. Regierer, Mikkel Østergaard, Andrea Götschi, Mariana Luís, Kristýna Bubová, Bente Glintborg, Caroline Ospelt, Corina Mogoşan, Žiga Rotar, Simon Horskjær Rasmussen, Marleen van de Sande, Cătălin Codreanu, Annik Steimer, Jonas Brändli
article en

Abstract

<h2>ABSTRACT</h2><h3>Objective</h3> To investigate possible variations in treatment response to secukinumab at distinct anatomic joint locations in patients with psoriatic arthritis (PsA) in routine clinical care. <h3>Methods</h3> Patients with PsA monitored in 9 registries contributing to the European Spondyloarthritis Research Collaboration Network were included in this study if at least 1 joint from the 28-joint count was clinically swollen at the start of treatment with secukinumab. The primary outcome was time to first resolution of clinical joint swelling at each joint location, excluding the shoulder, during a follow-up of 2 years. Estimated hazard ratios (HRs) for resolution between different joint locations were compared with interval-censored mixed-effects transformation models adjusted for age, sex, and previous biologic/targeted synthetic disease-modifying antirheumatic drug (DMARD). <h3>Results</h3> A total of 590 patients with 2794 swollen joints at the initiation of secukinumab were included (mean [SD] age 51.7 [12.3] years, 54% female patients, 77% co-treatment with conventional synthetic DMARDs). Compared with the wrist, the elbow had a higher rate of resolution of joint swelling (HR = 1.75, 95% CI=1.10-2.79). The metacarpophalangeal joints (MCP) 4 and 5 (HR = 2.01, 95% CI=1.40-2.88 and HR=1.98, 95% CI=1.28-3.06, respectively), as well as most proximal interphalangeal joints (PIP), except PIP3, had a higher rate of resolution compared with the wrist. No significant difference in the resolution of joint swelling was found for the wrist compared with MCP2, MCP3, PIP3, and the knee. <h3>Conclusions</h3> In PsA, the time to resolution of joint swelling after initiation of secukinumab differs between distinct joint locations.

EULAR Rheumatology OpenVol. 1(4)
University of Siena (IT), University of Bern (CH), Universidad Complutense de Madrid (ES), Reykjavík University (IS), University of Copenhagen (DK), Bursa Uludağ Üni̇versi̇tesi̇ (TR), University of Helsinki (FI), University of Ljubljana (SI), University of Iceland (IS), Tampere University (FI), Lund University (SE), University of Aberdeen (GB), University of Zurich (CH), Aarhus University (DK), Charles University (CZ), Helsinki University Hospital (FI), University Hospital of Bern (CH), Ljubljana University Medical Centre (SI), Glostrup Hospital (DK), Aarhus University Hospital (DK), Rigshospitalet (DK), Hospital General Universitario Gregorio Marañón (ES), Reade (NL), Institute of Rheumatology (CZ), German Rheumatism Research Centre (DE), East Tallinn Central Hospital (EE), University Hospital of Zurich (CH), Escola Superior de Tecnologia da Saúde de Coimbra (PT), University Hospital of Geneva (CH), National University Hospital of Iceland (IS), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), Kanta-Hämeen Keskussairaala (FI), Diakonhjemmet Hospital (NO), Tampere University Hospital (FI), Tampere University (FI), Skåne University Hospital (SE), Amsterdam University Medical Centers (NL), SCQM Foundation (CH), Sørlandet Sykehus (NO), Hospital do Desterro (PT), University of Bari Aldo Moro (IT), University of Amsterdam (NL)
Novartis Pharma
Openalex Percentile: Top 56%
Spondyloarthritis Studies and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.